Invention Grant
- Patent Title: Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy
-
Application No.: US16242950Application Date: 2019-01-08
-
Publication No.: US10849873B2Publication Date: 2020-12-01
- Inventor: Mitchell S. Steiner , Ramesh Narayanan , Sunjoo Ahn , James T. Dalton
- Applicant: GTx, Inc.
- Applicant Address: US CA San Diego
- Assignee: ONCTERNAL THERAPEUTICS, INC
- Current Assignee: ONCTERNAL THERAPEUTICS, INC
- Current Assignee Address: US CA San Diego
- Agency: Zedek Latzer Baratz LLP
- Agent Mark S. Cohen; Pearl Cohen
- Main IPC: A61K31/277
- IPC: A61K31/277 ; A61P35/00 ; A61K31/167 ; A61K31/404 ; A61K31/4704 ; A61K9/00 ; A61K9/06 ; A61K9/48 ; A61K9/10 ; A61K9/02 ; A61K9/16 ; A61K9/107 ; A61K9/08

Abstract:
This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and/or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
Public/Granted literature
Information query